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ABSTRACT
This paper describes the development process of the Pesquisa Nacional sobre Acesso, Utilização 
e Promoção do Uso Racional de Medicamentos (PNAUM – National Survey on Access, Use and 
Promotion of Rational Use of Medicines) based on an integrated approach to pharmaceutical 
services, science, technology and innovation. It starts by contextualizing health and development 
in Brazil and features elements of the National Policy for Science, Technology and Innovation 
in Health in Brazil and the National Policy for Pharmaceutical Services. On presenting 
pharmaceutical policy guidelines, it stresses the lack of nationwide data. This survey, 
commissioned by the Brazilian Ministry of Health, has two components: household survey and 
evaluation of pharmaceutical services in primary care. The findings point to perspectives that 
represent, besides the enhancement of public policy for pharmaceutical services and public 
health, results of government action aimed at developing the economic and industrial health 
care complex to improve the health conditions of the Brazilian population.
DESCRIPTORS: National Policy of Pharmaceutical Services. Innovation and Development Policy. 
Public Health Policy. Unified Health System.
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INTRODUCTION
This supplement of Revista de Saúde Pública ( Journal of Public Health) is a milestone 
in the field of pharmaceutical public policy in Brazil. It presents the results of the first 
nationwide survey on the subject and addresses the interface between pharmaceutical 
policy and policy for science, technology and innovation in health in Brazil. The 
Secretariat of Science, Technology and Strategic Inputs of the Brazilian Ministry of 
Health commissioned from research institutions of different Brazilian state and federal 
public universities the Pesquisa Nacional sobre Acesso, Utilização e Promoção do Uso 
Racional de Medicamentos (PNAUM – National Survey on Access, Use and Promotion 
of Rational Use of Medicines).
The opening article of this unprecedented and rich compilation features the 
development process of PNAUM based on an integrated approach to pharmaceutical 
services, science, technology and innovation. It begins by discussing the background of 
health development and of the National Policy for Science, Technology and Innovation 
in Health in Brazil; it presents a brief overview of research, science and innovation 
in health and the role of the Departments of Science and Technology (DECIT) and 
Pharmaceutical Services and Strategic Health Supplies (DAF), as well as the design 
process of this research and the perspectives of the Brazilian Ministry of Health for 
the development of strategies for pharmaceutical policy.
HEALTH AND DEVELOPMENT
The theme of health has been institutionalized and incorporated into the national 
development agenda, in the field of science, technology and innovation, because of its 
strategic nature. Health is an inherent component of the social dimension of development, 
for several reasons: it enables the care of human needs; it plays a significant role in the 
country’s economic development, generating employment and income with 14 million 
direct and five million indirect jobs, which, in 2009, accounted for approximately 9.0% of the 
gross domestic product; and it holds a leading position in terms of investment in research 
and development2. Thus, health is not only part of the welfare state and a basic condition of 
citizenship for the Brazilian population, but it also helps to generate employment, income 
and wealth in Brazil3.
Concerning research and development, much of the effort has been made in the field 
of health, integrated worldwide to a set of technologies related to an international and 
competitive standard of knowledge: nanotechnology, biotechnology, information and 
communication technology, among others3. In Brazil, public investment in research 
and development in health has reached significant levels since the organization of the 
2nd National Conference on Science, Technology and Innovation in Health in 2004. 
The health sector is the largest component of scientific and technological production 
in Brazil and several countries4.
In the social and economic life of nations, the incorporation of the advances in science, 
technology and innovation into the health sector contributes decisively to improve the 
living conditions of the population2.
LEGAL AND REGULATORY FRAMEWORK OF THE NATIONAL POLICY FOR 
SCIENCE, TECHNOLOGY AND INNOVATION IN HEALTH IN BRAZIL
Article 200, section V of the 1988 Federal Constitution establishes the competence of 
the Brazilian health system, which includes fostering the development of scientific and 
technological development in health. The National Policy for Science, Technology and 
Innovation in Health was formulated in 2004 as part of the National Health Policy of the 
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Brazilian Unified Health System (SUS)4, and of the National Policy for Science, Technology and 
Innovation, being subject to the same principles that govern the latter: technical-scientific 
merit and social relevance6,a.
The approval of the National Policy for Science, Technology and Innovation in Health in 
2004 was the result of a collective consensus on the relevance of implementing initiatives 
to foster science, technology and innovation, linked to SUS needs, in order to improve the 
fragile integration between support initiatives in science, technology and innovation and 
health policy. This collective effort involved, in all stages, fifteen thousand participants from 
the fields of health, science and technology, and education4.
The objective of the National Policy for Science, Technology and Innovation in Health, 
as well as of the National Policy for Science, Technology and Innovation, is to contribute 
to sustainable national development via the production of scientific and technological 
knowledge linked to the country’s economic, social, cultural and political needs4.
The creation of the Secretariat of Science, Technology and Strategic Inputs (SCTIE) in 2003 
led to the gradual and progressive incorporation into public health policy of issues and 
demands hitherto discussed in the areas of science, technology and innovation; on the other 
hand, it established more active interaction with the field of health. Thus, the creation of a 
secretariat with such a profile was a decisive factor in implementing the National Policy for 
Science, Technology and Innovation in Health4.
The SCTIE is divided into four departments: Pharmaceutical Services and Strategic Health 
Supplies, Science and Technology, Industrial Complex and Innovation in Health, and, more 
recently, Management and Incorporation of Health Tecnologya. The departments jointly seek 
to develop programs and activities by applying science, technology and innovation to the 
field of health, which comprises an intrinsic relationship between research and development; 
production and innovation; incorporation of technologies; health care, surveillance and 
support, as shown in Figure 1.
EVOLUTION OF SCIENTIFIC PRODUCTIVITY AND INCENTIVE TO SCIENCE, 
TECHNOLOGY AND INNOVATION IN HEALTH IN BRAZIL
According to SCImago Journal & Country Rank, in 2014 Brazil ranked 14th worldwide 
in absolute number of scientific articles on health published in journals indexed in 
the Scopus® database. As for scientific production in health between 1996 and 2014 
a Brasil. Decreto nº 8.065, 
de 7 de agosto de 2013. Aprova a 
Estrutura Regimental e o Quadro 
Demonstrativo dos Cargos 
em Comissão e das Funções 
Gratificadas do Ministério da 
Saúde e remaneja cargos em 
comissão. Brasília (DF): 2013 
[cited 2015 Jan 29]. Available 
from: http://www.planalto.gov.br/
ccivil_03/_Ato2011-2014/2013/
Decreto/D8065.htm
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Figure 1. Science, Technology and Innovation within the Brazilian Ministry of Health.
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among the BRICS countries (Brazil, Russia, India, China and South Africa), Brazil 
ranked 3rd, behind China and Indiab. In addition, scientific production in health in 
Brazil has grown significantly in the last two decades. In 1996, Brazil accounted for 
approximately 40.2% and 0.7% of scientific production in health in Latin America and 
worldwide, respectively. However, in 2014, these percentages increased to 55.2% and 
2.2%, respectivelyc.
Regarding support to health research in Brazil, disbursements in science, technology 
and innovation increased significantly in the last decade, totaling approximately 
R$4.5 billion (Figure 2).
THE ROLE OF DECIT FUNDING IN HEALTH RESEARCH IN BRAZIL
Since the creation of the Department of Science and Technology (DECIT) – by Decree 
3496 of June 1, 2000 – the Brazilian Ministry of Health has made significant advances 
in supporting health research in Brazil, as well as in formulating, implementing and 
evaluating the National Policy on Science, Technology and Innovation in Health, 
aiming to use scientific and technological knowledge at all SUS management levels. 
The research support modalities used by DECIT include national research public 
calls, decentralized funding (Research Program for the Unified Health System: Shared 
Management in Health), and direct financing. Between 2011 and 2015, 1,514 projects 
were funded, totaling approximately R$292 million invested by this department and 
its partnersd.
The national and international partnerships established by DECIT – such as Brazilian 
Development Bank, Coordination for the Improvement of Higher Education Personnel, 
Funding Authority for Studies and Projects, National Council for Scientific and 
Technological Development, Brazilian State Funding Agencies, State Health Departments, 
Bill & Melinda Gates Foundation, National Institute of Health, Agencia Argentina de 
Promoción Científica y Tecnológica, among others – has allowed increased investment by 
other institutions and the development of scientific cooperation networks at national and 
international level in strategic and priority research for the Brazilian Ministry of Health, 
aimed at strengthening SUS.
b Country Ranks of SCImago 
Journal & Country Rank. [cited 
2015 Nov 24]. Available from: 
http://www.scimagojr.com/
countryrank.php?area=2700&cat
egory=0&region=all&year=2014
&order=it&min=0&min_type=it
c SJR SCImago Journal & Country 
Rank. Country search: Brazil. 
[cited 2015 Nov 24]. Available 
from: http://www.scimagojr.com/
countrysearch.php?country=BR
d Ministério da Saúde. Pesquisa 
Saúde: Base de Dados 
Gerenciais do Decit/SCTIE/
MS. Brasília (DF); 2015 [cited 
2015 Nov 24]. Available from: 
http://200.214.130.94/bdgdecit/
index.php
800
700
600
500
400
300
200
100
0
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Biological Sciences Health Sciences
156
209 220 225
282 292 292
356 398
279
94
118 125 130
166 152 185
237
320
218
Source: Conselho Nacional de Desenvolvimento Científico e Tecnológico. CNPq investment panel. Brasília (DF); 
2015 [cited 2015 Nov 24]. Available from: http://www.cnpq.br/painel-de-investimentos
* Disbursements in 2015 between January 1 and November 24.
Figure 2. Evolution of CNPq/MCTI disbursements* to support research (grants in Brazil + grants 
abroad + research funding) in Health and Biological Sciences in millions of reais.
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DECIT SUPPORT IN PHARMACEUTICAL SERVICES
All DECIT support initiatives aim to fund research to strengthen the principles of SUS – the 
promotion of universality, equity, integrality and resoluteness. As for pharmaceutical services, 
via national and state (Research Program for the Unified Health System: Shared Management 
in Health) public notices and direct funding, DECIT financed approximately 228 studies in 
2011-2014, totaling R$33.5 million.
Acknowledging that the country lacked a national population-based survey to specifically 
identify aspects related to the National Policy for Pharmaceutical Services (PNAF)e, SCTIE 
invested more than R$9.4 million in PNAUM.
THE ROLE OF THE DEPARTMENT FOR PHARMACEUTICAL SERVICES AND 
STRATEGIC HEALTH SUPPLIES IN NATIONAL PHARMACEUTICAL POLICY
In recent years, integrated care, guaranteed by the Organic Law on Healthf, has been a focus 
of reflection and debate among managers, professionals, scholars in the field of health, 
the judiciary and other actors in society, regarding the principle of integrality, criteria to 
incorporate technology in health, and availability of medication for the population5.
To meet this requirement, pharmaceutical care was implemented as public policy at 
national level with the enactment of the National Medicines Policyg. This policy has 
the following main objectives: to ensure the safety, efficacy and quality of medicines; 
to promote the rational use of medicines; and to guarantee the population’s access to 
essential medicines5.
Improvements to the National Medicines Policy aimed to complement and enhance the 
proposals of pharmaceutical services in the country, in order to incorporate more explicitly 
the principles of universality, integrality and equity, and the initiatives for health promotion, 
protection and recovery established in SUS.
The PNAF was developed in 2004 based on an integrated approach, and is understood as 
public policy and an integral part of the National Health Policy7.
The resolution that enacted PNAFe defines pharmaceutical services as a set of initiatives for 
health promotion, protection and recovery, individually and collectively, using medicines as 
an essential input, aiming at access and rational use. This set of initiatives involves “research, 
development and production of medicines and inputs, as well as their selection, planning, 
procurement, distribution, dispensing, guarantee of product and service quality, monitoring 
and evaluation of use, in order to achieve concrete results and improve the quality of life of 
the population” (p.52)e.
The creation of the Department for Pharmaceutical Services and Strategic Health Supplies 
in 2013 institutionalized a national sector to develop and coordinate the National Medicines 
Policy in Brazil. The department’s responsibilities include: cooperating technically to improve 
the managerial and operational capacity of states and municipalities; promoting, regulating 
and coordinating the procurement and distribution of strategic inputs, at different levels 
of care; supporting, monitoring and evaluating the implementation of pharmaceutical care 
services and enhancing the quality of pharmaceutical services in SUS.
The Brazilian government has developed various initiatives to implement these policies and 
guarantee the population’s access to pharmaceutical services and medicines. These include 
Programa Farmácia Popular do Brasil (Brazilian Popular Pharmacy Program), in 2004; Política 
Nacional de Plantas Medicinais e Fitoterápicos (National Policy for Medicinal Plants and Herbal 
Medicines), in 2006; Componente Especializado da Assistência Farmacêutica (Specialized 
Component for Pharmaceutical Services), in 2009; Programa Nacional de Qualificação da 
Assistência Farmacêutica (National Program of Pharmaceutical Services Qualification), within 
e Ministério da Saúde, Conselho 
Nacional de Saúde. Resolução 
nº 338, de 6 de maio de 2004. 
Aprova a Política Nacional 
de Assistência Farmacêutica 
e estabelece seus princípios 
gerais e eixos estratégicos. 
Diario Oficial Uniao. 20 maio 
2004; Seção I.
f Brasil. Lei nº 8.080, de 19 de 
setembro de 1990. Dispõe sobre 
as condições para a promoção, 
proteção e recuperação da 
saúde, a organização e o 
funcionamento dos serviços 
correspondentes e dá outras 
providências. Diario Oficial 
Uniao. 20 set 1990; Seção 
I:18055. 
g Ministério da Saúde. Portaria 
nº 3.916, de 30 de outubro de 
1998. Aprova a Política Nacional 
de Medicamentos, cuja íntegra 
consta no anexo desta portaria. 
Diario Oficial Uniao. 10 nov 
1998; Seção 1:18-22.
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SUS (QUALIFAR-SUS), in 2012h, among others. Such policies are incentives for scientific, 
technological and innovation development in the Brazil.
In addition to public policies, programs and initiatives, the Brazilian Ministry of Health 
has provided and expanded investment in pharmaceutical services in the country, 
which increased from approximately R$2 billion in 2003 to around R$15 billion in 
2015 (Figure 3).
Increasing investment in pharmaceutical policy in Brazil requires from public managers 
information and rational planning focused on implementing such policy. Therefore, it has 
become imperative to obtain data which is more accurate and representative of access to 
medicines and of their rational use by the population. In this context, Pesquisa Nacional sobre 
Acesso, Utilização e Promoção do Uso Racional de Medicamentos (National Survey on Access, 
Use and Promotion of Rational Use of Medicines) is an institutional strategy to assess the 
impact of the implementation of medicines policy in Brazil.
It is necessary to assess whether government efforts to expand the access and guarantee 
of the benefits of pharmaceutical services to the population are helping to reduce the costs 
of medicines for families, and whether the resources invested have generated effective 
impacts on the health of the Brazilian population, such as the appropriate use of medicines 
in different population strata and major Brazilian regionsi.
NATIONAL SURVEY ON ACCESS, USE AND PROMOTION OF RATIONAL USE 
OF MEDICINES (PNAUM) 
The Brazilian Ministry of Health Decree 2077 of September 17, 2013, established the PNAUM, 
implemented by two coordinated strategies (components): the population component 
(survey) and the services component (assessment of pharmaceutical services in basic care). 
The overall objective of the survey is to evaluate the access, use, and rational use of medicines 
by the Brazilian population and their implementation in SUS basic care.
The survey component of PNAUM, coordinated by Universidade Federal do Rio Grande 
do Sul, consisted of a cross-sectional nationwide household survey; the first results of this 
component are presented in this supplement. The component assessing pharmaceutical 
h Ministério da Saúde. Portaria 
nº 1.214, de 13 de junho de 
2012. Institui o Programa 
Nacional de Qualificação da 
Assistência Farmacêutica no 
âmbito do Sistema Único de 
Saúde (QUALIFAR-SUS). Diario 
Oficial Uniao. 14 jun 2012; 
Seção I:29-30.
i Costa KS. Acesso e uso de 
medicamentos: inquéritos 
de saúde como estratégia de 
avaliação [these]. Campinas: 
Faculdade de Ciências Médicas 
da Universidade Estadual de 
Campinas; 2014 [cited 2015 Oct 
30]. Available from: http://www.
bibliotecadigital.unicamp.br/
document/?code=000928053
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Source: Brazilian Ministry of Health. National Health Fund – FNS and CGPLAN/SCTIE/MS [cited 2015 Nov 20]. 
Available from: http://www.fns.saude.gov.br
Figure 3. Evolution of disbursements (in billions of reais) by the Department of Pharmaceutical services 
and Strategic Inputs of the Brazilian Ministry of Health. Brazil, 2003-2005.
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services in primary care, coordinated by Universidade Federal de Minas Gerais, consisted 
of a qualitative and quantitative research aimed at evaluating public medicines policy in 
Brazilian primary health care (the findings shall be presented in a second issue on the theme).
The PNAUM development and consensus process, involving 11 state and federal public 
universities in different regions of the country, began with the formation of the research team 
in 2009, and was implemented in September 2013, with initial work in major Brazilian regions 
and municipalities. Executive oversight was carried out by representatives appointed by the 
Secretariat of Science, Technology and Strategic Inputs, members of the PNAUM steering 
committee, throughout the entire survey period, by on-site monitoring, participation in 
technical meetings and progress reports.
PERSPECTIVES OF THE BRAZILIAN HEALTH MINISTRY REGARDING 
PNAUM RESULTS
Based on consolidated and analyzed PNAUM data, the Brazilian Ministry of Health intends 
to advance and improve the implementation, monitoring and continuous evaluation of 
Brazilian pharmaceutical policy (National Medicines Policy and PNAF). The findings 
will make it possible to increase knowledge in the field, establish national indicators on 
access to and rational use of medicines in Brazil, prioritize strategic paths for policies 
and programs, assess government efforts in access to and guarantee of pharmaceutical 
services benefits, and publicize nationally and internationally the results obtained with 
different actors of society.
FINAL CONSIDERATIONS
The process of incorporating health technologies requires implementing structured records 
that enable analysis of impacts generated by such technologies, in line with the growing 
demands of different Brazilian economic and social sectors6.
As stated, the lack of consistent and standardized information and indicators on the evolution 
of the economic and industrial health care complex, pharmaceutical services, and the field 
of science, technology and innovation in health is restrictive not only in terms of production 
and evaluation, but also for the assimilation and consolidation of recommended or agreed 
indicator standards to support the implementation of policies8. Among the negative effects 
are limitations that prevent the incorporation of the impacts of scientific and technological 
development on the health of populations on a broader scale7.
In the context of this paper, heretofore Brazil had no data produced by nationwide scientific 
research, shared by academic institutions and health management agencies, exclusively 
related to pharmaceutical services. This type of evaluation provides potential support to 
guide government initiatives and public pharmaceutical policies to favor more equitable 
health action in the country and improve the health conditions and quality of life of the 
Brazilian population.
This supplement presents the first PNAUM findings on the population component. The 
survey team has designed the articles based on the specific set of objectives of the survey, 
in order to answer them. To this end, besides the methodological aspect of PNAUM, the 
topics addressed will include: global and free access to medicines; use of medicines in older 
adults, children and people with high blood pressure; use of generic medicines; catastrophic 
expenditure; self-medication; among others relevant to the area.
The scenario outlined in this article also sought to reflect on the seemingly more structuring 
measure recently introduced in science, technology and innovation in health under the 
Brazilian Ministry of Health: an integrating action of the various dimensions of health 
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development, addressing research support, incorporation of technological advances 
based on scientific grounds, and the level of production development in the economic and 
industrial health care complex, in order to provide access to health on an universal, integral 
and equitable basis.
The article also emphasizes a development approach in which, in addition to technical 
requirements, the concept of innovation also addresses the political and social process 
to reflect the ethical and social dimension inherent in innovation, which is linked to the 
fulfillment of human needs, as noted by Celso Furtado:
Development (...) can be defined as a process of social change in which the increasing 
number of human needs, pre-existing or created by actual change, are met by a 
differentiation in the production system, generated by the introduction of technological 
innovations (p. 39-40)8.
We therefore invite everyone to read this supplement, comprised of a series of articles 
considered highly relevant to public health in Brazil, hoping that its content may contribute 
to greater efficiency in the execution of public pharmaceutical policies, resulting in benefits 
to the health of the Brazilian population.
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